Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 43984 | 4.66 |
09:34 ET | 13035 | 4.65 |
09:36 ET | 6001 | 4.62 |
09:38 ET | 67791 | 4.545 |
09:39 ET | 15661 | 4.54 |
09:41 ET | 3383 | 4.525 |
09:43 ET | 7293 | 4.5401 |
09:45 ET | 6435 | 4.54 |
09:48 ET | 7727 | 4.58 |
09:50 ET | 2900 | 4.6 |
09:52 ET | 6289 | 4.59 |
09:54 ET | 3556 | 4.59 |
09:56 ET | 10432 | 4.55 |
09:57 ET | 3556 | 4.53 |
09:59 ET | 1200 | 4.525 |
10:01 ET | 3336 | 4.505 |
10:03 ET | 9744 | 4.55 |
10:06 ET | 1011 | 4.535 |
10:08 ET | 2821 | 4.53 |
10:10 ET | 8465 | 4.58 |
10:12 ET | 1021 | 4.6 |
10:14 ET | 3000 | 4.625 |
10:15 ET | 12510 | 4.655 |
10:17 ET | 11841 | 4.6988 |
10:19 ET | 15866 | 4.695 |
10:21 ET | 2329 | 4.695 |
10:24 ET | 4693 | 4.675 |
10:26 ET | 1100 | 4.685 |
10:28 ET | 2000 | 4.695 |
10:30 ET | 4383 | 4.69 |
10:32 ET | 1800 | 4.68 |
10:33 ET | 400 | 4.665 |
10:35 ET | 13928 | 4.715 |
10:37 ET | 16710 | 4.78 |
10:39 ET | 7739 | 4.8008 |
10:42 ET | 76921 | 4.755 |
10:44 ET | 6287 | 4.745 |
10:46 ET | 12605 | 4.725 |
10:48 ET | 5600 | 4.745 |
10:50 ET | 5929 | 4.75 |
10:51 ET | 2058 | 4.75 |
10:53 ET | 4871 | 4.765 |
10:55 ET | 1012 | 4.775 |
10:57 ET | 2449 | 4.755 |
11:00 ET | 24845 | 4.795 |
11:02 ET | 9155 | 4.78 |
11:04 ET | 23642 | 4.765 |
11:06 ET | 50654 | 4.8 |
11:08 ET | 19448 | 4.8301 |
11:09 ET | 10469 | 4.855 |
11:11 ET | 6539 | 4.875 |
11:13 ET | 9026 | 4.845 |
11:15 ET | 13395 | 4.83 |
11:18 ET | 13717 | 4.87 |
11:20 ET | 600 | 4.87 |
11:22 ET | 19303 | 4.855 |
11:24 ET | 6143 | 4.8408 |
11:26 ET | 3850 | 4.84 |
11:27 ET | 3904 | 4.845 |
11:29 ET | 8380 | 4.875 |
11:31 ET | 14436 | 4.87 |
11:33 ET | 1280 | 4.87 |
11:36 ET | 1326 | 4.8711 |
11:38 ET | 3173 | 4.865 |
11:40 ET | 100 | 4.875 |
11:42 ET | 3878 | 4.865 |
11:44 ET | 500 | 4.86 |
11:45 ET | 4393 | 4.87 |
11:47 ET | 10678 | 4.885 |
11:49 ET | 7833 | 4.87 |
11:51 ET | 2854 | 4.885 |
11:54 ET | 1600 | 4.885 |
11:56 ET | 12663 | 4.88 |
11:58 ET | 2535 | 4.865 |
12:00 ET | 1200 | 4.87 |
12:02 ET | 17984 | 4.875 |
12:03 ET | 6025 | 4.87 |
12:05 ET | 4846 | 4.88 |
12:07 ET | 8598 | 4.885 |
12:09 ET | 16666 | 4.9201 |
12:12 ET | 11085 | 4.94 |
12:14 ET | 3906 | 4.94 |
12:16 ET | 9507 | 4.94 |
12:18 ET | 7265 | 4.94 |
12:20 ET | 23126 | 4.9 |
12:21 ET | 38783 | 4.955 |
12:23 ET | 171882 | 4.975 |
12:25 ET | 23014 | 4.98 |
12:27 ET | 10073 | 4.975 |
12:30 ET | 477680 | 5.0024 |
12:32 ET | 4489 | 5.03 |
12:34 ET | 28285 | 5.01 |
12:36 ET | 11168 | 5.06 |
12:38 ET | 29298 | 5.09 |
12:39 ET | 83994 | 5.07 |
12:41 ET | 6437 | 5.1 |
12:43 ET | 31970 | 5.0999 |
12:45 ET | 5703 | 5.08 |
12:48 ET | 10431 | 5.075 |
12:50 ET | 35670 | 5.08 |
12:52 ET | 16042 | 5.03 |
12:54 ET | 23202 | 5.025 |
12:56 ET | 4035 | 5.045 |
12:57 ET | 15232 | 5.06 |
12:59 ET | 30740 | 5.1 |
01:01 ET | 188204 | 5.0807 |
01:03 ET | 13037 | 5.075 |
01:06 ET | 20006 | 5.065 |
01:08 ET | 14882 | 5.09 |
01:10 ET | 44591 | 5.15 |
01:12 ET | 25341 | 5.125 |
01:14 ET | 7342 | 5.14 |
01:15 ET | 6679 | 5.145 |
01:17 ET | 11118 | 5.165 |
01:19 ET | 5494 | 5.14 |
01:21 ET | 79604 | 5.1501 |
01:24 ET | 9165 | 5.17 |
01:26 ET | 8161 | 5.17 |
01:28 ET | 22694 | 5.1677 |
01:30 ET | 13454 | 5.135 |
01:32 ET | 142895 | 5.26 |
01:33 ET | 55431 | 5.19 |
01:35 ET | 22837 | 5.25 |
01:37 ET | 75008 | 5.26 |
01:39 ET | 13039 | 5.27 |
01:42 ET | 10317 | 5.285 |
01:44 ET | 93662 | 5.2065 |
01:46 ET | 27240 | 5.1805 |
01:48 ET | 10520 | 5.1602 |
01:50 ET | 32418 | 5.19 |
01:51 ET | 33159 | 5.2501 |
01:53 ET | 16944 | 5.245 |
01:55 ET | 5960 | 5.23 |
01:57 ET | 2917 | 5.235 |
02:00 ET | 28082 | 5.2371 |
02:02 ET | 8625 | 5.245 |
02:04 ET | 8689 | 5.22 |
02:06 ET | 5985 | 5.23 |
02:08 ET | 7685 | 5.225 |
02:09 ET | 24474 | 5.19 |
02:11 ET | 8052 | 5.175 |
02:13 ET | 11251 | 5.21 |
02:15 ET | 8580 | 5.18 |
02:18 ET | 10609 | 5.1508 |
02:20 ET | 46835 | 5.11 |
02:22 ET | 27880 | 5.165 |
02:24 ET | 15506 | 5.25 |
02:26 ET | 3225 | 5.2435 |
02:27 ET | 8102 | 5.2247 |
02:29 ET | 21292 | 5.21 |
02:31 ET | 20429 | 5.215 |
02:33 ET | 10912 | 5.1908 |
02:36 ET | 35461 | 5.23 |
02:38 ET | 5965 | 5.235 |
02:40 ET | 30504 | 5.22 |
02:42 ET | 27009 | 5.195 |
02:44 ET | 21100 | 5.195 |
02:45 ET | 27087 | 5.14 |
02:47 ET | 20735 | 5.17 |
02:49 ET | 26777 | 5.2109 |
02:51 ET | 6787 | 5.205 |
02:54 ET | 25421 | 5.175 |
02:56 ET | 7381 | 5.195 |
02:58 ET | 9064 | 5.2107 |
03:00 ET | 6325 | 5.225 |
03:02 ET | 15474 | 5.2775 |
03:03 ET | 31149 | 5.28 |
03:05 ET | 38477 | 5.32 |
03:07 ET | 25062 | 5.2811 |
03:09 ET | 12215 | 5.2709 |
03:12 ET | 12665 | 5.285 |
03:14 ET | 10069 | 5.255 |
03:16 ET | 21081 | 5.23 |
03:18 ET | 11890 | 5.2301 |
03:20 ET | 12799 | 5.205 |
03:21 ET | 6627 | 5.215 |
03:23 ET | 2359 | 5.2375 |
03:25 ET | 9478 | 5.205 |
03:27 ET | 8396 | 5.215 |
03:30 ET | 3482 | 5.205 |
03:32 ET | 12259 | 5.235 |
03:34 ET | 5173 | 5.235 |
03:36 ET | 18350 | 5.275 |
03:38 ET | 21788 | 5.275 |
03:39 ET | 19230 | 5.265 |
03:41 ET | 16346 | 5.295 |
03:43 ET | 20116 | 5.275 |
03:45 ET | 12331 | 5.2807 |
03:48 ET | 30569 | 5.305 |
03:50 ET | 51933 | 5.2899 |
03:52 ET | 35027 | 5.27 |
03:54 ET | 20555 | 5.285 |
03:56 ET | 102236 | 5.3101 |
03:57 ET | 71287 | 5.305 |
03:59 ET | 296910 | 5.31 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 3.1B | -3.5x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Apogee Therapeutics Inc | 3.1B | -30.1x | --- |
Xenon Pharmaceuticals Inc | 3.3B | -15.9x | --- |
Janux Therapeutics Inc | 3.2B | -45.9x | --- |
IDEAYA Biosciences Inc | 3.2B | -21.8x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.28 |
EPS | $-1.54 |
Book Value | $0.11 |
P/E Ratio | -3.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.